drugset / Trial / NCT05458011

A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine

NCT05458011

Phase 3 Completed 365 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

Primary Objective: To demonstrate the efficacy of fremanezumab administered as monthly and quarterly subcutaneous (sc) injections to adult Chinese participants with migraine. Secondary Objectives: * To further demonstrate the efficacy of fremanezumab administered as monthly and quarterly sc injections. * To evaluate the safety and tolerability of fremanezumab administered as monthly and quarterly sc injections.

Timeline

Start
2022-09-30
Primary completion
2024-01-31
Completion
2024-06-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Fremanezumab Monoclonal antibody Subcutaneous

Indications